Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 4, 2003, Pages 159-164

  Barre J ^a   Ledudal, P ^a   Oosterhuis, B ^b   Brakenhoff, J P G ^b   Wilkens, G ^b   Sollie, F A E ^b   Tran, D ^b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b PRA International USA   (Netherlands)

Author keywords

Elderly; Pharmacokinetics; Renal failure; Trimetazidine

Indexed keywords

TRIMETAZIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; GERIATRIC PATIENT; HEADACHE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGING; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; TABLETS; TRIMETAZIDINE;

EID: 0037799427     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.350     Document Type: Article

References (6)

1. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-588.
2. Jackson PJ, Brownsill RD, Taylor AR, Resplandy G, Walther B, Schwietert HR. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica 1996; 26: 221-228.
3. World Medical Association. Declaration of Helsinki. Guiding Physicians in Biomedical Research Involving Human Subjects. JAMA 1997; 277: 925-926.
4. Oulsnam I, Taylor AR, Ings B, Campbell B. Etude de la captation et de la distribution de la trimétazidine dans les globules et le muscle lisse. Gaz Med 1984; 91 (suppl. 26): 71-77.
5. Sellier P, Broustet JP. Efficacy at trough and safety of trimetazidine MR 35 mg in patients with stable angina pectoris. Abstract accepted at the 10th International Congress on Cardiovascular Pharmacotherapy-March 27-30, 2001-Kyoto (Japan) Cardiovasc Drugs Ther 2001; 15 (Suppl.): 18.
6. Emeriau JP, Royer RJ, Laveille C, Pennaforte S. Long term clinical safety of trimetazidine MR 35 mg (bid per os) in elderly patients (age ≥ 75 years): a double-blind placebo-controlled study with population pharmacokinetics. Servier Internal Report NP7403.